Lucamont Plus Dosage

How do you administer this medicine?
sponsored

Consists of Desloratadine, Montelukast

Dosage of Desloratadine (Lucamont Plus) in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

Desloratadine (Lucamont Plus) Dosage

Generic name: Desloratadine 5mg

Dosage form: tablet, film coated; oral solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Although an orally disintegrating tablet formulation of desloratadine may be available in the marketplace, Desloratadine (Lucamont Plus)® RediTabs® Tablets are no longer marketed.

Desloratadine (Lucamont Plus) Tablets,

Oral Solution, or RediTabs Tablets may be taken without regard to meals. Place Desloratadine (Lucamont Plus) (desloratadine) RediTabs Tablets on the tongue and allow to disintegrate before swallowing. Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister.

The age-appropriate dose of Desloratadine (Lucamont Plus)

Oral Solution should be administered with a commercially available measuring dropper or syringe that is calibrated to deliver 2 mL and 2.5 mL (½ teaspoon).

Adults and Adolescents 12 Years of Age and Over

The recommended dose of Desloratadine (Lucamont Plus) Tablets or Desloratadine (Lucamont Plus) Tablets is one 5-mg tablet once daily. The recommended dose of Desloratadine (Lucamont Plus)

Oral Solution is 2 teaspoonfuls (5 mg in 10 mL) once daily.

Children 6 to 11 Years of Age

The recommended dose of Desloratadine (Lucamont Plus)

Oral Solution is 1 teaspoonful (2.5 mg in 5 mL) once daily. The recommended dose of Desloratadine (Lucamont Plus) Tablets is one 2.5-mg tablet once daily.

Children 12 Months to 5 Years of Age

The recommended dose of Desloratadine (Lucamont Plus)

Oral Solution is ½ teaspoonful (1.25 mg in 2.5 mL) once daily.

Children 6 to 11 Months of Age

The recommended dose of Desloratadine (Lucamont Plus)

Oral Solution is 2 mL (1 mg) once daily.

Adults with Hepatic or Renal Impairment

In adult patients with liver or renal impairment, a starting dose of one 5-mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data.

More about Desloratadine (Lucamont Plus) (desloratadine)

Consumer resources

Professional resources

Other formulations

Related treatment guides

What other drugs will affect Desloratadine (Lucamont Plus)?

There may be other drugs that can interact with desloratadine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Desloratadine (Lucamont Plus) interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Desloratadine (Lucamont Plus), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Inhibitors Of Cytochrome P450 3A4

In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine.

Fluoxetine

In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine.

Cimetidine

In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine.

Drug Abuse And Dependence

There is no information to indicate that abuse or dependency occurs with Desloratadine (Lucamont Plus) Tablets.

Dosage of Montelukast (Lucamont Plus) in details

The dose of a drug and dosage of the drug are two different terminologies. Dose is defined as the quantity or amount of medicine given by the doctor or taken by the patient at a given period. Dosage is the regimen prescribed by the doctor about how many days and how many times per day the drug is to be taken in specified dose by the patient. The dose is expressed in mg for tablets or gm, micro gm sometimes, ml for syrups or drops for kids syrups. The dose is not fixed for a drug for all conditions, and it changes according to the condition or a disease. It also changes on the age of the patient.
sponsored

General Recommendations: The therapeutic effect of Montelukast on parameters of asthma control occurs within one day. Patients should be advised to continue taking Montelukast even if their asthma is under control, as well as during periods of worsening asthma.

Montelukast (Lucamont Plus) as an Alternative Treatment Option to Low-Dose Inhaled Corticosteroids for Mild Persistent Asthma: Montelukast is not recommended as monotherapy in patients with moderate persistent asthma. The use of montelukast as an alternative treatment option to low-dose inhaled corticosteroids for children with mild persistent asthma should only be considered for patients who do not have a recent history of serious asthma attacks that required oral corticosteroid use and who have demonstrated that they are not capable of using inhaled corticosteroids. Mild persistent asthma is defined as asthma symptoms more than once a week but less than once a day, nocturnal symptoms more than twice a month but less than once a week and normal lung function between episodes. If satisfactory control of asthma is not achieved at follow-up (usually within one month), the need for an additional or different anti inflammatory therapy based on the step system for asthma therapy should be evaluated. Patients should be periodically evaluated for their asthma control.

Montelukast (Lucamont Plus) 4 mg: Montelukast (Lucamont Plus) as Prophylaxis of Asthma for 2 to 5 Year Old Patients in Whom the Predominant Component is Exercise-Induced Bronchoconstriction: In 2 to 5 year old patients, exercise-induced bronchoconstriction may be the predominant manifestation of persistent asthma that requires treatment with inhaled corticosteroids. Patients should be evaluated after 2 to 4 weeks of treatment with montelukast. If satisfactory response is not achieved, an additional or different therapy should be considered.

Therapy with Montelukast (Lucamont Plus) in Relation to Other Treatments for Asthma: When treatment with Montelukast is used as add-on therapy to inhaled corticosteroids, Montelukast should not be abruptly substituted for inhaled corticosteroids.

Montelukast (Lucamont Plus) 4 mg: This medicinal product is to be given to a child under adult supervision. For children who have problems consuming a chewable tablet, an adapted formulation should be used (e.g. granule formulation). The dosage for pediatric patients 2-5 years of age is one 4 mg chewable tablet daily to be taken in the evening. If taken in connection with food, Montelukast should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary. Montelukast 4 mg chewable tablet formulation is not recommended below 2 years of age.

The dosage is the same for both male and female patients.

5 mg chewable tablets are available for pediatric patients 6 to 14 years of age.

Montelukast (Lucamont Plus) 5 mg: The dosage for pediatric patients 6-14 years of age is one 5 mg chewable tablet daily to be taken in the evening. lf taken in connection with food, Montelukast should be taken 1 hour before or 2 hours after food. No dosage adjustment within this age group is necessary.

The dosage is the same for both male and female patients.

Renal Impairment: No dosage adjustment is necessary for patients with renal insufficiency.

Hepatic Impairment: No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment.

Montelukast (Lucamont Plus) 10 mg: The dosage for adults 15 years of age and older with asthma or with asthma and concomitant seasonal allergic rhinitis is one 10 mg tablet daily to be taken in the evening.

General Recommendations: The therapeutic effect of Montelukast sodium (Montelukast (Lucamont Plus)) on parameters of asthma control occurs within one day. Montelukast sodium (Montelukast (Lucamont Plus)) may be taken with or without food. Patients should be advised to continue taking Montelukast sodium (Montelukast (Lucamont Plus)) even if their asthma is under control, as well as during periods of worsening asthma. Montelukast sodium (Montelukast (Lucamont Plus)) should not be used concomitantly with other products containing the same active ingredient, montelukast.

No dosage adjustment is necessary for the elderly, or for patients with renal insufficiency, or mild to moderate hepatic impairment. There are no data on patients with severe hepatic impairment. The dosage is the same for both male and female patients.

Therapy with Montelukast Sodium (Montelukast (Lucamont Plus)) in Relation to Other Treatments for Asthma: Montelukast sodium (Montelukast (Lucamont Plus)) can be added to a patient's existing treatment regimen.

Inhaled Corticosteroids: Treatment with Montelukast sodium (Montelukast (Lucamont Plus)) can be used as add-on therapy in patients when inhaled corticosteroids plus "as needed" short acting β-agonists provide inadequate clinical control. Montelukast sodium (Montelukast (Lucamont Plus)) should not be abruptly substituted for inhaled corticosteroids.

What other drugs will affect Montelukast (Lucamont Plus)?

Tell your doctor about all other medicines you use, especially:

This list is not complete and other drugs may interact with montelukast. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Montelukast (Lucamont Plus) interactions

Interactions are the effects that happen when the drug is taken along with the food or when taken with other medications. Suppose if you are taking a drug Montelukast (Lucamont Plus), it may have interactions with specific foods and specific medications. It will not interact with all foods and medications. The interactions vary from drug to drug. You need to be aware of interactions of the medicine you take. Most medications may interact with alcohol, tobacco, so be cautious.
sponsored

Montelukast may be administered with other therapies routinely used in the prophylaxis and chronic treatment of asthma, and in the treatment of allergic rhinitis. In drug-interactions studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: Theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol/norethindrone 35/1), terfenadine, digoxin and warfarin.

The area under the plasma concentration-time curve (AUC) for montelukast was decreased approximately 40% in subjects with co-administration of phenobarbital. No dosage adjustment for Montelukast is recommended.

In vitro studies have shown that montelukast is an inhibitor of CYP2C8. However, data from a clinical drug-drug interaction study involving montelukast and rosiglitazone (a probe substrate representative of drugs primarily metabolized by CYP2C8) demonstrated that montelukast does not inhibit CYP2C8 in vivo. Therefore, montelukast is not anticipated to alter the metabolism of drugs metabolized by this enzyme (e.g. paclitaxel, rosiglitazone, and repaglinide.)

In vitro studies have shown that montelukast is a substrate of CYP 2C8, 2C9, and 3A4. Data from a clinical drug-drug interaction study involving montelukast and gemfibrozil (an inhibitor of both CYP 2C8 and 2C9) demonstrated that gemfibrozil increased the systemic exposure of montelukast by 4.4-fold.

Co-administration of itraconazole, a strong CYP 3A4 inhibitor, with gemfibrozil and montelukast did not further increase the systemic exposure of montelukast. The effect of gemfibrozil on systemic exposure of montelukast is not considered to be clinically meaningful based on clinical safety data with doses greater than the 10 mg approved dose in adults (e.g., 200 mg/day to adult patients for 22 weeks, and up to 900 mg/day to patients for approximately one week) where clinically important adverse experiences were not observed. Therefore, no dosage adjustment of montelukast is required upon co-administration with gemfibrozil. Based on in vitro data, clinically important drug interactions with other known inhibitors of CYP 2C8 (e.g., trimethoprim) are not anticipated. In addition, co-administration of montelukast with itraconazole alone resulted in no significant increase in the systemic exposure of montelukast.



References

  1. DailyMed. "DESLORATADINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. FDA/SPL Indexing Data. "MHM278SD3E: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Lucamont Plus are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lucamont Plus. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported frequency of use

No survey data has been collected yet


1 consumer reported doses

What doses of Lucamont Plus drug you have used?
The drug can be in various doses. Most anti-diabetic, anti-hypertensive drugs, pain killers, or antibiotics are in different low and high doses and prescribed by the doctors depending on the severity and demand of the condition suffered by the patient. In our reports, ndrugs.com website users used these doses of Lucamont Plus drug in following percentages. Very few drugs come in a fixed dose or a single dose. Common conditions, like fever, have almost the same doses, e.g., [acetaminophen, 500mg] of drug used by the patient, even though it is available in various doses.
Users%
6-10mg1
100.0%


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 18 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2022 ndrugs.com All Rights Reserved